Introduction:
ABO blood group compatibility is a critical factor in renal transplantation, with ABO-compatible transplants demonstrating superior graft and patient survival outcomes. However, with advancements in immunosuppressive therapy, ABO incompatible (ABOi) transplants are feasible. This study done to compare the efficacy of ATG and ATLG as induction agents in ABOi renal transplant patients
Methods:
This retrospective analysis of 198 patients (>18 years) who underwent ABOi renal transplantation between 2015 to 2022. Patients received either ATG (n=124) or ATLG (n=74) as induction therapy, in addition to Desensatization therapy as per our centre protocol.
Outcomes were assessed in terms of graft survival, infection rates, biopsy-proven rejection, and patient survival at 12 months.
Results:
The mean age of recipients in the ATG group was 40.8±12.6 years (83.87% male), compared to 43±11.78 years (86% male) in the ATLG group. The mean donor age was 49.5±10.79 years (83.7% female) in the ATG group and 50.56±10.08 years (83% female) in the ATLG group. ATG recipients received a mean cumulative dose of 144.35±46 mg, while ATLG recipients received 333.88±102 mg.
At 12 months, patient survival was 98(79.03%) in the ATG group and 66(89.2%) in the ATLG group (p=0.29).
The combined biopsy proven rejection rate was 25 (20.16%) in the ATG group, compared to 13(17.6%) in the ATLG group(p=0.70).
Graft survival was comparable in both the groups 75.8% in ATG vs 83.7% in ATLG Group with (p=0.45).
Most common infection observed was UTI – ATG (26,20.9%) and in ATLG (15,20.2%) cases(p<0.05).
Conclusions:
Both ATG and ATLG are effective induction therapies for ABOi renal transplant recipients, with comparable patient survival and graft function at 12 months.
I have no potential conflict of interest to disclose.
I did not use generative AI and AI-assisted technologies in the writing process.